Ankylosing Spondylitis (AS) and Inflammatory Bowel Disease (IBD) Overlap: Crohn's, UC, and the Shared Biology

ankylosing spondylitis and inflammatory bowel disease Overlap — scientific infographic poster

Table of Contents

  1. The Numbers — How Often They Overlap
  2. Why They Cluster — The Shared Biology
  3. Symptoms of Inflammatory Bowel Disease to Watch For if You Have Ankylosing Spondylitis
  4. Screening Ankylosing Spondylitis Patients for Occult Inflammatory Bowel Disease
  5. Symptoms of Ankylosing Spondylitis to Watch For if You Have Inflammatory Bowel Disease
  6. Screening Inflammatory Bowel Disease Patients for Ankylosing Spondylitis
  7. How Inflammatory Bowel Disease Overlap Changes Biologic Selection
  8. The “Best Single Drug” Question for Ankylosing Spondylitis + Inflammatory Bowel Disease
  9. When Inflammatory Bowel Disease Develops on an IL-17 Inhibitor
  10. Gut-Directed Approaches That Help Both
  11. Nonsteroidal Anti-Inflammatory Drugs in Ankylosing Spondylitis + Inflammatory Bowel Disease — The Conflict
  12. Monitoring Co-Managed Disease
  13. Other Extraintestinal Manifestations Connecting Ankylosing Spondylitis and Inflammatory Bowel Disease
  14. Pregnancy and Ankylosing Spondylitis+Inflammatory Bowel Disease Overlap
  15. Key Research Papers
  16. Connections
  17. Featured Videos

1. The Numbers — How Often They Overlap

If you have ankylosing spondylitis (AS) and you’ve noticed you also run to the bathroom more than your friends, you’re not imagining it. Ankylosing spondylitis and inflammatory bowel disease (IBD) — Crohn’s disease and ulcerative colitis — are two ends of the same biological rope.

Roughly 10% of ankylosing spondylitis patients develop clinical inflammatory bowel disease over their lifetime, with Crohn’s being more common than ulcerative colitis. A UK study of 4,101 people with ankylosing spondylitis found that 3.7% already had inflammatory bowel disease when ankylosing spondylitis was diagnosed and that the 20-year cumulative incidence was 7.5% for inflammatory bowel disease (24.5% for acute anterior uveitis); the risk of inflammatory bowel disease was 3.3 times that of matched controls and highest in the first years after diagnosis. That number climbs dramatically when you look under the microscope: 30–60% of ankylosing spondylitis patients have subclinical gut inflammation visible on colonoscopy with biopsy, even when they have no gastrointestinal (GI) symptoms at all. In a Belgian cohort of 65 people with spondyloarthritis who had ileocolonoscopy, 46.2% had microscopic gut inflammation; in axial disease it was linked to male sex, high disease activity, restricted spinal mobility and younger age. The bowel is inflamed; the patient just doesn’t feel it yet.

The traffic runs both ways. 10–20% of inflammatory bowel disease patients have ankylosing spondylitis or another form of spondyloarthritis, and inflammatory back pain is the single most common extraintestinal manifestation of inflammatory bowel disease. Both conditions cluster in families that carry human leukocyte antigen-B27, and both live inside the same IL-23/IL-17 cytokine pathway. When you treat one, you are often — whether you know it or not — treating the other.

2. Why They Cluster — The Shared Biology

The IL-23/IL-17 Axis

The dominant unifying theme is the IL-23/IL-17 axis. IL-23 is produced by dendritic cells and macrophages at mucosal surfaces — the gut especially — and it drives a population of T cells and innate lymphoid cells to release IL-17 and tumor necrosis factor-α. Those cytokines inflame the gut wall, the entheses (where tendon meets bone), and the sacroiliac joints. The same inflammatory cocktail, in different tissues.

Gut Dysbiosis

The intestinal microbiome of ankylosing spondylitis patients looks abnormal in the same way inflammatory bowel disease microbiomes look abnormal: reduced diversity, expansion of pro-inflammatory species, loss of butyrate-producing commensals. Whether dysbiosis causes the disease or is caused by it is still argued, but the overlap in microbial signatures is striking.

Intestinal Permeability

Both ankylosing spondylitis and inflammatory bowel disease patients show increased intestinal permeability — the so-called “leaky gut.” Bacterial lipopolysaccharide and peptidoglycan fragments cross the gut wall and enter systemic circulation, where they can trigger inflammation at distant sites, including the spine.

Shared Genetics

Several susceptibility genes are shared: human leukocyte antigen-B27, IL23R, ERAP1, CARD9, STAT3, and others. These genes sit inside the innate immune response and antigen processing pipeline — the exact machinery that decides when to treat a gut bacterium as a threat.

Molecular Mimicry

Some of the most durable hypotheses invoke molecular mimicry. Peptides from gut bacteria — notably Klebsiella pneumoniae and certain E. coli strains — bear structural similarity to self-peptides that human leukocyte antigen-B27 presents, creating a crossfire where an anti-bacterial immune response ends up attacking joint and gut tissue. See Starch-Free Diet and the Ebringer Hypothesis and human leukocyte antigen-B27 Explained for the mechanistic detail.

3. Symptoms of Inflammatory Bowel Disease to Watch For if You Have Ankylosing Spondylitis

If you have ankylosing spondylitis, your inflammation doesn’t only live in your spine. These signs point to possible inflammatory bowel disease and are common reasons for a gastrointestinal referral:

4. Screening Ankylosing Spondylitis Patients for Occult Inflammatory Bowel Disease

Because subclinical gut inflammation is so common, a reasonable screening tier looks like this:

Abnormal results are the usual point at which a gastroenterologist becomes involved. The Crohn’s Disease page covers the full workup pathway.

5. Symptoms of Ankylosing Spondylitis to Watch For if You Have Inflammatory Bowel Disease

If you already carry an inflammatory bowel disease diagnosis and you start noticing back pain, it is not necessarily a desk-chair problem. Inflammatory back pain has a fingerprint:

6. Screening Inflammatory Bowel Disease Patients for Ankylosing Spondylitis

The screening workup for ankylosing spondylitis in inflammatory bowel disease patients is relatively simple and high-yield:

7. How Inflammatory Bowel Disease Overlap Changes Biologic Selection

This is where the overlap matters most practically. A biologic that is a home run for axial ankylosing spondylitis can be a disaster for inflammatory bowel disease — and vice versa. Get this decision wrong and you can trigger a flare in the organ you weren’t even targeting.

Drugs That Treat BOTH Axial Ankylosing Spondylitis and Inflammatory Bowel Disease

Drugs That Treat Ankylosing Spondylitis but Do NOT Treat (and May Worsen) Inflammatory Bowel Disease

Drugs That Treat Inflammatory Bowel Disease but Not Axial Ankylosing Spondylitis

Emerging Options

Risankizumab and guselkumab are IL-23 selective inhibitors, effective for inflammatory bowel disease and psoriatic arthritis. In the spine they have not shown benefit: a 2018 placebo-controlled phase 2 trial of risankizumab in 159 people with active ankylosing spondylitis failed its main goal — at week 12, 15.0% on the 180 mg dose reached the ASAS40 response vs 17.5% on placebo — and showed no evidence of clinically meaningful improvement; the authors suggested IL-23 may not be a relevant driver of ankylosing spondylitis.

The gut side shows the mirror image. In a 2012 trial in 59 people with moderate-to-severe Crohn’s disease, the IL-17A blocker secukinumab was ineffective (the authors called the results “unexpected”): Crohn’s activity scores favoured placebo, and 20 infections occurred on secukinumab vs none on placebo. Together these trials explain why IL-23 drugs help the gut but not the spine, while IL-17 drugs help the spine but not the gut, and why the TNF-blocking antibodies above remain the drugs that cover both.

See the Biologics Guide for dosing, safety monitoring, and how to sequence agents.

8. The “Best Single Drug” Question for Ankylosing Spondylitis + Inflammatory Bowel Disease

For most patients with overlapping ankylosing spondylitis and inflammatory bowel disease, the answer is simple: adalimumab or infliximab. Both have decades of prospective trial and registry data in both conditions, and both are genuinely effective at controlling axial, peripheral, and intestinal disease.

Choosing between them is mostly a lifestyle call. Infliximab is loaded and maintained by infusion every 6–8 weeks in an infusion center, which suits severe or difficult-to-control inflammatory bowel disease (the dose can be escalated and the interval shortened quickly). Adalimumab is a self-administered subcutaneous injection every 2 weeks, more convenient for stable disease and for patients who dislike infusion chairs.

Biosimilars are now available for both drugs and are often the insurance-preferred option, typically at a fraction of the branded price with equivalent efficacy.

9. When Inflammatory Bowel Disease Develops on an IL-17 Inhibitor

This is a scenario rheumatologists see more often as IL-17 agents become popular. A patient on secukinumab or ixekizumab for ankylosing spondylitis starts passing bloody stools and is diagnosed with new-onset inflammatory bowel disease. What now?

Rheumatologists typically stop the IL-17 inhibitor and switch to a tumor necrosis factor-α inhibitor (most commonly adalimumab or infliximab). IL-17 inhibition-triggered inflammatory bowel disease often reverses once the drug is stopped, especially if caught early. A gastroenterologist usually manages induction therapy — sometimes a short course of steroids is used to quiet the flare while the new biologic takes effect.

10. Gut-Directed Approaches That Help Both

Non-pharmacologic interventions that target the gut have plausible dual benefit:

11. Nonsteroidal Anti-Inflammatory Drugs in Ankylosing Spondylitis + Inflammatory Bowel Disease — The Conflict

Nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line pain control in ankylosing spondylitis, and for good reason — they work, and they may even slow radiographic progression when taken continuously. But they can worsen inflammatory bowel disease flares and cause mucosal ulceration, creating a direct conflict in overlap patients.

How clinicians commonly handle the conflict:

See nonsteroidal anti-inflammatory drug (NSAID) Strategy for the full risk-benefit framework.

12. Monitoring Co-Managed Disease

If you have both conditions, the ideal setup is a rheumatologist and a gastroenterologist who share notes. Typically a single biologic is prescribed and monitored by the rheumatologist while the gastroenterologist tracks disease activity from the inflammatory bowel disease side.

13. Other Extraintestinal Manifestations Connecting Ankylosing Spondylitis and Inflammatory Bowel Disease

Both diseases share a portfolio of extraintestinal manifestations that can precede, accompany, or follow the index diagnosis:

14. Pregnancy and Ankylosing Spondylitis+Inflammatory Bowel Disease Overlap

Biologic choice becomes even more critical in pregnancy. Certolizumab pegol is the preferred agent for patients trying to conceive or already pregnant because its lack of an Fc region means minimal placental transfer to the fetus. Adalimumab and infliximab are also considered compatible through much of pregnancy but are typically timed carefully in the third trimester.

Disease activity tends to improve during the first trimester (pregnancy’s natural immunomodulation) but flares are common postpartum, so close follow-up and early re-dosing of the biologic after delivery are usual. See Pregnancy and ankylosing spondylitis for the full roadmap.

Key Research Papers

  1. Van Praet L, Van den Bosch FE, Jacques P, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis. 2013;72(3):414–417. — PubMed PMID: 23139267
  2. Ward MM, et al. 2019 Update of the ACR/SAA/SPARTAN Recommendations for the Treatment of Axial Spondyloarthritis. Arthritis & Rheumatology. 2019. — doi:10.1002/art.41042
  3. Harbord M, Annese V, Vavricka SR, et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. Journal of Crohn’s and Colitis. 2016;10(3):239–254. — doi:10.1093/ecco-jcc/jjv213
  4. Hueber W, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–1700. — doi:10.1136/gutjnl-2011-301668 (demonstrates IL-17 inhibitor harm in IBD)
  5. Baeten D, Østergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77(9):1295–1302. — PubMed PMID: 29945918
  6. Stolwijk C, Essers I, van Tubergen A, et al. The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. Ann Rheum Dis. 2015;74(7):1373–1378. — PubMed PMID: 24658834

PubMed Topic Searches

Curated PubMed topic searches for ankylosing spondylitis and inflammatory bowel disease overlap. Each link opens a live PubMed query so you always see the most current studies.

  1. PubMed: Ankylosing spondylitis and inflammatory bowel disease
  2. PubMed: Spondyloarthritis and subclinical gut inflammation
  3. PubMed: IL-17 inhibitors and Crohn’s disease
  4. PubMed: Anti-TNF in AS and Crohn’s
  5. PubMed: Fecal calprotectin in spondyloarthritis
  6. PubMed: HLA-B27 and inflammatory bowel disease
  7. PubMed: Gut-joint axis in spondyloarthritis
  8. PubMed: Vedolizumab and spondyloarthritis

Back to Table of Contents

Connections

Back to Table of Contents